GlassScriptPhysician profile
Susan Mobley Greene
NPI 1063718187
$2,313.51
in general payments reported to CMS, 2019-2025
29 companies · $509 in 2025
The $509 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $180 · 2021: $293 · 2022: $213 · 2023: $186 · 2024: $451 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.25 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $228.26 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $226.15 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $177.42 | 2019-2025 | |
| Lupin INC. | $142.66 | 2019-2021 | |
| Sage Therapeutics, LLC | $117.33 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $114.46 | 2022-2025 | Omni Hysteroscope, Acessa Provu System, Myosure Tissue Removal Device |
| Myovant Sciences INC. | $108.16 | 2021-2022 | |
| Lilly USA, LLC | $106.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Exeltis, USA INC. | $105.13 | 2021-2025 | Slynd |
| Biogen, INC. | $99.82 | 2025 | Zurzuvae |
| Novo Nordisk INC | $69.15 | 2021-2022 | |
| Pfizer INC. | $67.30 | 2019-2025 | |
| Shield Therapeutics INC | $59.07 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $56.79 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $48.30 | 2021 | |
| Amgen INC. | $41.40 | 2019-2025 | Otezla, Repatha |
| Allergan, INC. | $37.20 | 2019-2020 | |
| Exact Sciences Corporation | $32.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gebauer Company | $29.43 | 2025 | |
| Mayne Pharma Commercial LLC | $26.22 | 2024 | |
| Merck Sharp & Dohme LLC | $25.58 | 2022-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amag Pharmaceuticals, INC. | $20.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.49 | 2024 | Rexulti |
| Scynexis, INC. | $16.39 | 2022 | |
| Smith+Nephew, INC. | $16.11 | 2023 | Stravix |
| Dermira, INC. | $15.37 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.